Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInventory AverageInvested Capital

Syndax Pharmaceuticals (SNDX) EBIT Margin (2016 - 2020)

Historic EBIT Margin for Syndax Pharmaceuticals (SNDX) over the last 6 years, with Q4 2020 value amounting to 5226.32%.

  • Syndax Pharmaceuticals' EBIT Margin fell 14881600.0% to 5226.32% in Q4 2020 from the same period last year, while for Dec 2020 it was 4708.17%, marking a year-over-year decrease of 9152300.0%. This contributed to the annual value of 1434.43% for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q4 2020, Syndax Pharmaceuticals' EBIT Margin is 5226.32%, which was down 14881600.0% from 5238.26% recorded in Q3 2020.
  • Syndax Pharmaceuticals' EBIT Margin's 5-year high stood at 1633.61% during Q4 2017, with a 5-year trough of 5238.26% in Q3 2020.
  • For the 5-year period, Syndax Pharmaceuticals' EBIT Margin averaged around 4195.8%, with its median value being 4351.46% (2017).
  • Its EBIT Margin has fluctuated over the past 5 years, first soared by 297691800bps in 2016, then plummeted by -34540200bps in 2018.
  • Syndax Pharmaceuticals' EBIT Margin (Quarter) stood at 3652.79% in 2016, then skyrocketed by 55bps to 1633.61% in 2017, then crashed by -211bps to 5087.63% in 2018, then increased by 27bps to 3738.16% in 2019, then tumbled by -40bps to 5226.32% in 2020.
  • Its EBIT Margin stands at 5226.32% for Q4 2020, versus 5238.26% for Q3 2020 and 4382.59% for Q2 2020.